New national hepatitis C virus (HCV) screening guidance from the United States Preventive Services Task Force includes a recommendation for one-time testing for all adults aged 18 to 79 years. Implicit in the new guidance is that all people diagnosed with chronic HCV infection should be offered HCV treatment.
This is a preview of subscription content, log in via an institution to check access.
References
World Health Organization. Global health strategy on viral hepatitis 2016–2021 (WHO, 2016).
Dore, G. J., Martinello, M., Alavi, M. & Grebely, J. Global elimination of hepatitis C virus by 2030: why not? Nat. Med. 26, 157–160 (2020).
Yehia, B. R., Schranz, A. J., Umscheid, C. A. & Lo Re, V. 3rd. The treatment cascade for chronic hepatitis C virus infection in the United States: a systematic review and meta-analysis. PLoS One 9, e101554 (2014).
US Preventive Services Task Force. Screening for hepatitis C virus infection in adolescents and adults: US Preventive Services Task Force Recommendation Statement. JAMA https://doi.org/10.1001/jama.2020.1123 (2020).
Dore, G. J. & Hajarizadeh, B. Elimination of hepatitis C virus in Australia: laying the foundation. Infect. Dis. Clin. North Am. 32, 269–279 (2018).
Chou, R. et al. Screening for hepatitis C virus infection in adolescents and adults: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA https://doi.org/10.1001/jama.2019.20788 (2020).
US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02683005 (2020).
Samuel, S. T., Martinez, A. D., Chen, Y., Markatou, M. & Talal, A. H. Hepatitis C virus knowledge improves hepatitis C virus screening practices among primary care physicians. World J. Hepatol. 10, 319–328 (2018).
Springer, S. A., Merluzzi, A. P. & Del Rio, C. Integrating responses to the opioid use disorder and infectious disease epidemics: a report from the National Academies of Sciences, Engineering, and Medicine. JAMA https://doi.org/10.1001/jama.2020.2559 (2020).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The Kirby Institute is funded by the Australian Government Department of Health and Ageing. The views expressed in this publication do not necessarily represent the position of the Australian Government. G.J.D. is an advisory board member of and has received honoraria from Merck, Gilead Sciences and AbbVie, and has received research grant funding from Merck, Gilead Sciences and AbbVie, as well as travel sponsorship from Merck, Gilead Sciences and AbbVie. G.V.M. has received research grant funding from AbbVie and Gilead Sciences.
Rights and permissions
About this article
Cite this article
Dore, G.J., Matthews, G.V. Universal screening for hepatitis C virus infection should be linked to universal treatment access. Nat Rev Gastroenterol Hepatol 17, 321–322 (2020). https://doi.org/10.1038/s41575-020-0306-8
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41575-020-0306-8
- Springer Nature Limited
This article is cited by
-
Universal screening for hepatitis C — in for a penny, in for a pound
European Journal of Clinical Microbiology & Infectious Diseases (2022)